OPKO Health (NASDAQ:OPK) Sees Strong Trading Volume – Still a Buy?

OPKO Health, Inc. (NASDAQ:OPK) shares saw strong trading volume on Monday . 4,977,027 shares were traded during trading, an increase of 178% from the previous session’s volume of 1,793,125 shares.The stock last traded at $1.46 and had previously closed at $1.48.

Analyst Ratings Changes

Several research firms recently issued reports on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Finally, StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Tuesday.

OPKO Health Stock Performance

The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -7.79 and a beta of 1.63. The stock’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.50.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. The trade was a 0.05 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 1,304,255 shares of company stock valued at $2,024,605. 47.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP increased its holdings in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares in the last quarter. Y.D. More Investments Ltd acquired a new position in shares of OPKO Health during the 2nd quarter worth approximately $1,840,000. PFG Investments LLC lifted its stake in OPKO Health by 10.4% in the 3rd quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock valued at $1,581,000 after buying an additional 100,125 shares in the last quarter. Finally, Clearline Capital LP purchased a new stake in OPKO Health in the 3rd quarter valued at approximately $1,083,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.